Biogen (BIIB) has put fresh attention on its spinal muscular atrophy pipeline after sharing new Phase 1b salanersen data showing sustained neurodegeneration biomarker reductions and motor milestone ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results